Economic sustainability of immune-checkpoint inhibitors: the looming threat. Issue 12 (December 2018)

• Record Type: Journal Article
• Authors: Verma, Vivek
• Is Part Of: Nature reviews. Volume 15:Issue 12(2018)
• Page Start: 721
• Page End: 722
• Publication Date: 2018-12
• Subjects: Cancer -- Treatment -- Periodicals; Cancer -- Periodicals; Oncology -- Periodicals; 616.994
• DOI: 10.1038/s41571-018-0086-z
• Languages: English
• ISSNs: 1759-4774

Abstract

Immune-checkpoint inhibitors (ICIs) are transforming oncology, but the mounting costs of cancer care necessitate concerns regarding economic sustainability. Here, several strategies that clinicians could use to exercise economically prudent administration of ICIs are discussed. These include better appraisal of the cost-effectiveness literature, judicious patient selection, separating statistical from clinical significance, and careful patient counselling.